PT KALBE FARMA TBK. PRESS RELEASE No. 048/KFCP-DIR/PR/VII/22
Jakarta, 25 July 2022, PT Kalbe Farma Tbk ("Kalbe") is pleased to announce the signing of a Share Purchase Agreement ("SPA") that took place on 22 July 2022, between Sanofi (Sanofi Aventis Participations and Hoechst GMBH) as Sellers and Kalbe as Purchaser. The SPA outlined the agreement between Kalbe and Sellers to transfer the majority share ownership in PT Aventis Pharma, which is expected to be effectively implemented in Q4 2022 subject to the fulfillment of certain conditions as part of the SPA.
The deal will transfer 80% ownership stake of Sellers in PT Aventis Pharma to Kalbe including manufacturing site in Jakarta, assets and distribution and marketing rights of Sanofi's prescription medicines and vaccines in Indonesia. The transaction will ensure continued manufacturing and supply of products to the Indonesian market through a long-term commitment in all aspects of distribution and licensing between Kalbe and Sanofi Group.
"This strategic move will bring onboard complimentary products that are well aligned with Kalbe's portfolio, particularly in the focus therapeutic classes such as diabetes and cardiovascular, as well as access to vaccines as part of our growth strategy. We look forward to this strategic collaboration with Sanofi as an innovative global healthcare company with strong market presence in Indonesia. We believe this will be a positive milestone in strengthening our position in the Indonesian pharmaceutical market, and to provide sustainable access to medicines for Indonesia," Kalbe's President Director Vidjongtius stated.
"As part of its long-term strategy, Sanofi is engaged in simplifying its international operations, while assessing how patients in the world can secure sustainable access to our medicines and vaccines.We are very proud of our long-standing presence in Indonesia with our employees and partners, and to open a new chapter with Kalbe to unleash the potential of growth of Indonesia market. We selected Kalbe for their trusted presence, robust business performance in the market and strong knowledge of Indonesia's healthcare landscape, that will secure broad and sustainable access to our medicines and vaccines for patients," said Haissam Chraiteh, Sanofi Head of Community Asia & Eurasia
About PT Kalbe Farma Tbk
PT Kalbe Farma Tbk (Kalbe) was established in 1966 and is one of the largest publicly listed pharmaceutical companies in Southeast Asia. Kalbe has four main divisions that handle a reliable and diverse brand portfolio; prescription drugs division, health products division which handles over-the-counter drugs, multivitamins and ready-to-drink supplements, nutrition division; and distribution & logistics division.
Kalbe now has more than 40 subsidiaries and 15 production facilities with international standards, and employs approximately 16,000 employees, spread across 76 branches throughout Indonesia. Since 1991, Kalbe's shares have been listed on the Indonesia Stock Exchange (IDX: KLBF).
About Sanofi
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people's lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
PT Kalbe Farma Tbk published this content on 25 July 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 July 2022 09:23:03 UTC.
